Age
Female sex
|
0.99 (0.97-1.01)
0.94 (0.56-1.56)
|
0.19
0.82
|
Diagnosis
MPA
GPA
|
1
1.90 (1.12-3.22)
|
0.02
|
Antigenic specificity
Anti-MPO
Anti-PR3
|
1
2.34 (1.38-3.97)
|
0.002
|
ANCA pattern
Monophasic
Remitting
Persistent
Recurrent
|
1
0.91 (0.26-3.24)
3.36 (1.29-8.79)
4.31 (1.78-10.42)
|
0.88
0.01
0.001
|
Clinical features
Constitutional symptoms
Fever
Anemia
Microhaematuria
Renal failure
Alveolar haemorrhage
Pulmonary infiltrates
Pulmonary nodules
Mononeuritis multiplex
CNS involvement
ENT involvement
Purpura
Arthritis
Ocular involvement
|
0.65 (0.36-1.16)
0.63 (0.37-1.09)
0.99 (0.40-2.50)
0.73 (0.42-1.29)
0.58 (0.34-0.98)
1.09 (0.62-1.91)
1.66 (0.90-3.06)
1.24 (0.67-2.27)
1.40 (0.68-2.87)
2.83 (0.86-9.29)
2.36 (1.38-4.03)
1.22 (0.57-2.58)
1.82 (1.07-3.12)
2.34 (1,10-4.99)
|
0.15
0.10
0.99
0.28
0.04
0.78
0.10
0.49
0.36
0.09
0.002
0.61
0.03
0.03
|
Treatment
Cyclophosphamide
Azathioprine
Methotrexate
Mycophenolic acid
Plasmapheresis
Rituximab
|
0.68 (0.32-1.42)
1.74 (1.02-2.98)
2.72 (1.38-5.36)
1.41 (0.77-2.60)
0.50 (0.20-1.27)
2.10 (1.20-3.68)
|
0.30
0.04
0.004
0.27
0.15
0.009
|